Ovid Therapeutics Inc
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
OVID$2.80-1.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| (in thousands) | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(10,235) | $(11,694) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Unrealized (gain) loss on equity investment | 66 | (4,397) |
| Change in accrued interest and accretion of discount on marketable securities | (197) | (921) |
| Stock-based compensation expense | 1,284 | 1,968 |
| Depreciation and amortization expense | 141 | 136 |
| Non-cash operating lease expense | 288 | 266 |
| Change in lease liability | (325) | (303) |
| Change in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (60) | 853 |
| Accounts payable | (1,242) | (107) |
| Accrued expenses | (1) | (2,486) |
| Net cash used in operating activities | (10,280) | (16,686) |
| Cash flows from investing activities: | ||
| Purchase of marketable securities | (4,898) | (9,793) |
| Sales/maturities of marketable securities | 10,000 | 30,000 |
| Purchases of property and equipment | — | (19) |
| Net cash provided by investing activities | 5,102 | 20,188 |
| Cash flows from financing activities: | ||
| Proceeds from exercise of options and purchases from employee stock purchase plan | 13 | 228 |
| Net cash provided by financing activities | 13 | 228 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (5,165) | 3,731 |
| Cash, cash equivalents and restricted cash, at beginning of period | 28,232 | 28,972 |
| Cash, cash equivalents and restricted cash, at end of period | $23,067 | $32,703 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.